Again, you are wrong. The drug actually looks even more appealing now, hence why they changed the endpoint to a significantly more difficult endpoint to meet. The data is blinded so they don’t know what drug is working but they can clearly see a specific cohort in the study is grossly outperforming the other cohort. Remdesivir did the opposite btw. They moved to an easier endpoint before the trial was complete in fear of not meeting it.
News 
Market Data 
Discover 
